Author

S. R. Rao

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Research Focus:trajectory inference· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. Agarwal· 1 shared A. D. Lamb· 1 shared A. Hayes· 1 shared A. Lambert· 1 shared A. Lazarides· 1 shared A. Omer· 1 shared B. Vojnovic· 1 shared C. Eward· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Agarwal

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole genome sequencing with histopathological features

S. R. Rao, C. Verrill, L. Cerundolo, N. K. Alham, Z. Kaya, M. O'Hanlon, A. Hayes, A. Lambert, M. James, I. D. C. Tullis, J. Niederer, S. Lovell, A. Omer, F. Lopez, T. Leslie, , F. C. Hamdy

This study integrates multi-region whole genome sequencing with histopathological data to reconstruct tumour phylogenies and identify molecular steps in prostate cancer progression and metastasis.

bioRxiv · Feb 27, 2023Cancer Biology

A cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma

J. Somarelli, G. Rupprecht, E. Altunel, E. Flamant, S. R. Rao, D. Sivaraj, A. Lazarides, S. Hoskinson, M. Sheth, S. Cheng, S. Y. Kim, K. Ware, A. Agarwal, M. Cullen, L. Selmic, , D. Hsu

This study develops a cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma, finding that dual inhibition of proteasome and CRM1 pathways induces synergistic cytotoxicity.

bioRxiv · Oct 19, 2020Cancer Biology